Know Cancer

or
forgot password

Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate


Phase 2
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate


OBJECTIVES:

- Provide treatment with intravenous antineoplastons A10 and AS2-1 for patients with
incurable adenocarcinoma of the prostate who failed to respond to treatment with
antineoplaston A10 and AS2-1 capsules.

- Describe response to, tolerance to, and side effects of this regimen in these patients.

OUTLINE: This is an open-label study.

Patients receive gradually increasing doses of antineoplaston A10 and antineoplaston AS2-1
by intravenous injection 6 times daily until the maximum tolerated dose is reached.

Treatment continues for at least 2 months in the absence of unacceptable toxicity or disease
progression. Patients achieving complete response (CR) continue treatment for an additional
8 months after reaching CR.

Tumors are measured every 2 months for 1 year and then every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed incurable stage IV adenocarcinoma of the prostate that
failed to respond to treatment with antineoplaston A10 and AS2-1 capsules and for
which no curative therapy exists

- Evidence of tumor by MRI or CT scan

- No prostate-specific antigen (PSA) response to antiandrogen withdrawal

- If PSA changes used to indicate progressive disease, then PSA must increase more than
50% on two determinations at least 2 weeks apart

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 60-100%

Life expectancy:

- At least 2 months

Hematopoietic:

- Hemoglobin at least 9 g/dL

- WBC at least 2000/mm^3

- Platelet count at least 50,000/mm^3

Hepatic:

- No hepatic insufficiency

- Bilirubin no greater than 2.5 mg/dL

- SGOT and SGPT no greater than 5 times upper limit of normal

Renal:

- Creatinine no greater than 2.5 mg/dL

- No history of renal conditions that contraindicate high dosages of sodium

Cardiovascular:

- No known chronic heart failure

- No uncontrolled hypertension

- No history of congestive heart failure

- No history of other cardiovascular conditions that contraindicate high dosages of
sodium

Pulmonary:

- No serious lung disease, such as severe chronic obstructive pulmonary disease

Other:

- Fertile patients must use effective contraception during and for 4 weeks after study
participation

- Not a high medical or psychiatric risk

- No concurrent nonmalignant systemic disease that would preclude therapy

- No active infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior immunotherapy and recovered

Chemotherapy:

- At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

- See Disease Characteristics

- At least 4 weeks since prior hormonal therapy and recovered

- Concurrent corticosteroids allowed if dose is stable or decreasing

Radiotherapy:

- At least 4 weeks since prior radiotherapy and recovered

Surgery:

- Recovered from prior surgery

Other:

- Prior cytodifferentiating agents allowed

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Stanislaw R. Burzynski, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Burzynski Research Institute

Authority:

United States: Federal Government

Study ID:

CDR0000066581

NCT ID:

NCT00003534

Start Date:

August 1998

Completion Date:

Related Keywords:

  • Prostate Cancer
  • adenocarcinoma of the prostate
  • stage IV prostate cancer
  • recurrent prostate cancer
  • Adenocarcinoma
  • Prostatic Neoplasms

Name

Location

Burzynski ClinicHouston, Texas  77055-6330